Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Abstract P2-26-23: Transcriptomic modification induced by the first cycle of neoadjuvant chemotherapy impacts response to treatment in triple negative breast cancer (TNBC)

Isabelle Desmoulins, David Chardin, Corentin Richard, Laurent Arnould, ALEXANDRE COCHET, Olivier Humbert, Romain Boidot

Cancer Res (2023) 83 (5_Supplement): P2-26-23.

https://doi.org/10.1158/1538-7445.SABCS22-P2-26-23

Published: 01 March 2023

View article titled, Abstract P2-26-23: Transcriptomic modification induced by the first cycle of neoadjuvant chemotherapy impacts response to treatment in triple negative breast cancer (TNBC)

Journal Articles

Abstract PD17-02: ctDNA Molecular Response based on breast cancer driver mutations predicts progression in aromatase inhibitor-sensitive first line treatment of oestrogen receptor-positive (ER+) HER2-negative (HER2-) advanced breast cancer

Cancer Res (2023) 83 (5_Supplement): PD17-02.

https://doi.org/10.1158/1538-7445.SABCS22-PD17-02

Published: 01 March 2023

View article titled, Abstract PD17-02: ctDNA Molecular Response based on breast cancer driver mutations predicts progression in aromatase inhibitor-sensitive first line treatment of oestrogen receptor-positive (ER+) HER2-negative (HER2-) advanced breast cancer

Journal Articles

Abstract 1296: MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells

Cancer Res (2022) 82 (12_Supplement): 1296.

https://doi.org/10.1158/1538-7445.AM2022-1296

Published: 15 June 2022

View article titled, Abstract 1296: MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells

Journal Articles

Abstract GS3-05: Fulvestrant-palbociclib vs continuing aromatase inhibitor-palbociclib upon detection of circulating ESR1 mutation in HR+ HER2- metastatic breast cancer patients: Results of PADA-1, a UCBG-GINECO randomized phase 3 trial

Cancer Res (2022) 82 (4_Supplement): GS3-05.

https://doi.org/10.1158/1538-7445.SABCS21-GS3-05

Published: 15 February 2022

View article titled, Abstract GS3-05: Fulvestrant-palbociclib vs continuing aromatase inhibitor-palbociclib upon detection of circulating ESR1 mutation in HR+ HER2- metastatic breast cancer patients: Results of PADA-1, a UCBG-GINECO randomized phase 3 trial

Journal Articles

Abstract P1-07-01: Real time detection of ESR1 mutation in blood by droplet digital PCR in the PADA-1 trial: Feasibility and cross-validation with NGS

Cancer Res (2022) 82 (4_Supplement): P1-07-01.

https://doi.org/10.1158/1538-7445.SABCS21-P1-07-01

Published: 15 February 2022

View article titled, Abstract P1-07-01: Real time detection of ESR1 mutation in blood by droplet digital PCR in the PADA-1 trial: Feasibility and cross-validation with NGS

Journal Articles

Abstract P5-02-04: Upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast to reduce inter-observer variability: The DCISion study

Cancer Res (2020) 80 (4_Supplement): P5-02-04.

https://doi.org/10.1158/1538-7445.SABCS19-P5-02-04

Published: 15 February 2020

View article titled, Abstract P5-02-04: Upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast to reduce inter-observer variability: The DCISion study

Journal Articles

Abstract P2-16-14: HER2-positive breast cancer: Combined ¹⁸F-FDG PET and CGFL/Curie nomogram to predict pathologic complete response after preoperative chemotherapy with trastuzumab

Laura Vincent, Clémentine Jankowski, Marion Cortet, Laurent Arnould, Sylvain Ladoire, Bruno Coudert, Isabelle Desmoulins, Céline Charron-Barra, Françoise Beltjens, Roman Rouzier, Fabien Reyal, Olivier Humbert, Alexandre Cochet, Charles Coutant

Cancer Res (2020) 80 (4_Supplement): P2-16-14.

https://doi.org/10.1158/1538-7445.SABCS19-P2-16-14

Published: 15 February 2020

View article titled, Abstract P2-16-14: HER2-positive breast cancer: Combined 18F-FDG PET and CGFL/Curie nomogram to predict pathologic complete response after preoperative chemotherapy with trastuzumab

Journal Articles

Abstract P3-08-25: Simosein registry, the French national real-life prospective evaluation of the impact of Endopredict® (EPclin) on treatment decision in ER-positive, HER2-negative breast cancers

Jacqueline Lehmann-Che, Jennifer Wong, Lucie Tixier, Ludovic Lacroix, Magali Triki-Lacroix, Pierre-Jean Lamy, Agnes Garnier, Véronique Quillien, Florence Godey, Isabelle Soubeyran, Gaëtan MacGrogan, Laurent Arnould, Juliette Haudebourg, Anne Tallet, Linda Dainese, Caroline Hugonin, Frédérique Penault-Llorca

Cancer Res (2020) 80 (4_Supplement): P3-08-25.

https://doi.org/10.1158/1538-7445.SABCS19-P3-08-25

Published: 15 February 2020

View article titled, Abstract P3-08-25: Simosein registry, the French national real-life prospective evaluation of the impact of Endopredict® (EPclin) on treatment decision in ER-positive, HER2-negative breast cancers

Journal Articles

Cleaved Caspase-3 Transcriptionally Regulates Angiogenesis-Promoting Chemotherapy Resistance

Antoine Bernard, Sandy Chevrier, Françoise Beltjens, Magalie Dosset, Etienne Viltard, Anaïs Lagrange, Valentin Derangère, Alexandra Oudot, François Ghiringhelli, Bertrand Collin, Lionel Apetoh, Olivier Feron, Suzie Chen, Laurent Arnould, Frédérique Végran, Romain Boidot

Cancer Res (2019) 79 (23): 5958–5970.

https://doi.org/10.1158/0008-5472.CAN-19-0840

Published: 02 December 2019

View article titled, Cleaved Caspase-3 Transcriptionally Regulates Angiogenesis-Promoting Chemotherapy Resistance

Includes: Supplementary data

Journal Articles

Abstract 5015: Innovative and predictive models against breast cancer

Olivier Duchamp, Severine Tabone-Eglinger, Caroline Mignard, Isabelle Goddard, Alain Bruno, Maia Chanrion, Loreley Calvet, Olivier Degoul, Kevin Dhondt, Liliane Goetsch, Julie Miralves, Christophe Lautrette, Cindy Pensec, Françoise Le Vacon, Isabelle Treilleux, Laurent Arnould, Philippe Vaglio, Grégoire Prevost, Olivier Tredan

Cancer Res (2017) 77 (13_Supplement): 5015.

https://doi.org/10.1158/1538-7445.AM2017-5015

Published: 01 July 2017

View article titled, Abstract 5015: Innovative and predictive models against breast cancer

Journal Articles

Abstract 5203: Innovative and predictive models against cancer: an IMODI integrative approach

Cancer Res (2016) 76 (14_Supplement): 5203.

https://doi.org/10.1158/1538-7445.AM2016-5203

Published: 15 July 2016

View article titled, Abstract 5203: Innovative and predictive models against cancer: an IMODI integrative approach

Journal Articles

Survivin-3B Potentiates Immune Escape in Cancer but Also Inhibits the Toxicity of Cancer Chemotherapy

Frédérique Végran, Romain Mary, Anne Gibeaud, Céline Mirjolet, Bertrand Collin, Alexandra Oudot, Céline Charon-Barra, Laurent Arnould, Sarab Lizard-Nacol, Romain Boidot

Cancer Res (2013) 73 (17): 5391–5401.

https://doi.org/10.1158/0008-5472.CAN-13-0036

Published: 02 September 2013

View article titled, Survivin-3B Potentiates Immune Escape in Cancer but Also Inhibits the Toxicity of Cancer Chemotherapy

Includes: Supplementary data

Journal Articles

Abstract 87: Micropapillary breast carcinoma is characterized by deregulation of genes involved in cell division control

Cancer Res (2012) 72 (8_Supplement): 87.

https://doi.org/10.1158/1538-7445.AM2012-87

Published: 15 April 2012

View article titled, Abstract 87: Micropapillary breast carcinoma is characterized by deregulation of genes involved in cell division control

Journal Articles

Abstract 8: Genomic analyses of heterogeneous HER2 3+ invasive ductal carcinomas of the breast

Arnaud Gauthier, Maryou Lambros, Daniel N. Rodrigues, Laurent Arnould, Magali Lacroix-Tikri, Frédérique Penault-Llorca, Marie-Christine Baranzelli, Xavier Sastre, Rachael Natrajan, Olivier Delattre, Paul Cottu, Jorge Sergio Reis-Filho, Anne Vincent-Salomon

Cancer Res (2012) 72 (8_Supplement): 8.

https://doi.org/10.1158/1538-7445.AM2012-8

Published: 15 April 2012

View article titled, Abstract 8: Genomic analyses of heterogeneous HER2 3+ invasive ductal carcinomas of the breast

Journal Articles

Pathological and immunophenotypical response to trastuzumab-containing primary systemic therapy in HER2 positive breast cancer. Arguments in favor of antibody-dependent cellular cytotoxicity (ADCC)

Laurent Arnould, Marion Gelly, Frederique Penault-Llorca, Franck Bonnetain, Colette Migeon, Veronique Cabaret, Veronique Fermeaux, Philippe Berteau, Laurent Benoit, Jerome Garnier, Bruno Coudert

Cancer Res (2005) 65 (9_Supplement): 1007.

Published: 01 May 2005

View article titled, Pathological and immunophenotypical response to trastuzumab-containing primary systemic therapy in HER2 positive breast cancer. Arguments in favor of antibody-dependent cellular cytotoxicity (ADCC)

Journal Articles

Absence of Genetic Abnormalities in Fibroadenomas of the Breast Determined at p53 Gene Mutations and Microsatellite Alterations

Noreli Franco, Samy-Félix Picard, Florence Mege, Laurent Arnould, Sarab Lizard-Nacol

Cancer Res (2001) 61 (21): 7955–7958.

Published: 01 November 2001

View article titled, Absence of Genetic Abnormalities in Fibroadenomas of the Breast Determined at p53 Gene Mutations and Microsatellite Alterations

Journal Articles

Concurrent and Independent Genetic Alterations in the Stromal and Epithelial Cells of Mammary Carcinoma: Implications for Tumorigenesis

Farid Moinfar, Yan Gao Man, Laurent Arnould, Gary L. Bratthauer, Manfred Ratschek, Fattaneh A. Tavassoli

Cancer Res (2000) 60 (9): 2562–2566.

Published: 01 May 2000

View article titled, Concurrent and Independent Genetic Alterations in the Stromal and Epithelial Cells of Mammary Carcinoma: Implications for Tumorigenesis

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract P2-26-23: Transcriptomic modification induced by the first cycle of neoadjuvant chemotherapy impacts response to treatment in triple negative breast cancer (TNBC)

Abstract PD17-02: ctDNA Molecular Response based on breast cancer driver mutations predicts progression in aromatase inhibitor-sensitive first line treatment of oestrogen receptor-positive (ER+) HER2-negative (HER2-) advanced breast cancer

Abstract 1296: MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells

Abstract GS3-05: Fulvestrant-palbociclib vs continuing aromatase inhibitor-palbociclib upon detection of circulating ESR1 mutation in HR+ HER2- metastatic breast cancer patients: Results of PADA-1, a UCBG-GINECO randomized phase 3 trial

Abstract P1-07-01: Real time detection of ESR1 mutation in blood by droplet digital PCR in the PADA-1 trial: Feasibility and cross-validation with NGS

Abstract P5-02-04: Upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast to reduce inter-observer variability: The DCISion study

Abstract P2-16-14: HER2-positive breast cancer: Combined ¹⁸F-FDG PET and CGFL/Curie nomogram to predict pathologic complete response after preoperative chemotherapy with trastuzumab

Abstract P3-08-25: Simosein registry, the French national real-life prospective evaluation of the impact of Endopredict® (EPclin) on treatment decision in ER-positive, HER2-negative breast cancers

Cleaved Caspase-3 Transcriptionally Regulates Angiogenesis-Promoting Chemotherapy Resistance

Abstract 5015: Innovative and predictive models against breast cancer

Abstract 5203: Innovative and predictive models against cancer: an IMODI integrative approach

Survivin-3B Potentiates Immune Escape in Cancer but Also Inhibits the Toxicity of Cancer Chemotherapy

Abstract 87: Micropapillary breast carcinoma is characterized by deregulation of genes involved in cell division control

Abstract 8: Genomic analyses of heterogeneous HER2 3+ invasive ductal carcinomas of the breast

Pathological and immunophenotypical response to trastuzumab-containing primary systemic therapy in HER2 positive breast cancer. Arguments in favor of antibody-dependent cellular cytotoxicity (ADCC)

Absence of Genetic Abnormalities in Fibroadenomas of the Breast Determined at p53 Gene Mutations and Microsatellite Alterations

Concurrent and Independent Genetic Alterations in the Stromal and Epithelial Cells of Mammary Carcinoma: Implications for Tumorigenesis

Email alerts

AACR Journals

Resources

AACR Journals
on Social Media

Update search

Email alerts

AACR Journals

Resources

AACR Journals on Social Media

This Feature Is Available To Subscribers Only

AACR Journals
on Social Media